Company intelligence / Profile preview
Parkure
Motherwell / Glasgow*, Scotland, United Kingdomparkure.co.uk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Parkure focuses on early-stage discovery and preclinical development of small molecule drugs to halt neurodegeneration in Parkinson’s disease. Their approach leverages genetically engineered fruit flies to rapidly screen compounds. Lead candidates are in preclinical or IND-enabling stages; no clinical trial results reported yet.
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Contracts with third-party pharmaceutical companies for compound testing using their fly-based screening approach.
Beyond the preview
Go deeper on Parkure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Parkure.